Surface marker expression of parental and EBV-infected PEL cells
Cell line . | CD11a . | CD18 . | CD23 . | CD30 . | CD39 . | CD40 . | CD54 . | CD58 . | CD74 . | CD138 . |
|---|---|---|---|---|---|---|---|---|---|---|
| BC3 | 2.9 | 2.6 | 2.0 | 82.2 | 2.8 | 1.9 | 66.3 | 72.9 | 65 | 67.6 |
| BC-3 GFP EBV cl-6 | 9.3 | 8.2 | 8.0 | 6.2 | 5.1 | 9.2 | 66.0 | 67.3 | 5.0 | 60.9 |
| BC-3 GFP EBV cl-10 | 7.1 | 9.0 | 6.4 | 14.2 | 5.1 | 11.6 | 63.3 | 70.0 | 8.6 | 66.4 |
| CRO-AP/6 | 14.2 | 11.5 | 1.0 | 80.0 | 1.6 | 7.3 | 66.9 | 82.4 | 78.3 | 81.5 |
| CRO-AP/6 GFPEBV cl-1 | 11.3 | 14.9 | 11.1 | 25.3 | 19.0 | 11.1 | 69.7 | 71.7 | 12.3 | 78.3 |
| CRO-AP/6 GFPEBV cl-2 | 25.5 | 27.8 | 5.1 | 12.2 | 4.4 | 14.9 | 78.6 | 77.7 | 7.9 | 85.0 |
| CRO-AP/3 | 4.7 | 12.8 | 11 | 59.11 | 5 | 10.6 | 11.9 | 19.3 | 60 | 71.6 |
| CRO-AP/3 GFPEBV cl-1 | 4.9 | 9.2 | 6.5 | 12.8 | 4 | 5.3 | 4.3 | 5 | 11.2 | 17.9 |
| CRO-AP/3 GFPEBV cl-2 | 7 | 4.7 | 6.1 | 13.2 | 4.7 | 1 | 4.2 | 2.4 | 10.3 | 22 |
Cell line . | CD11a . | CD18 . | CD23 . | CD30 . | CD39 . | CD40 . | CD54 . | CD58 . | CD74 . | CD138 . |
|---|---|---|---|---|---|---|---|---|---|---|
| BC3 | 2.9 | 2.6 | 2.0 | 82.2 | 2.8 | 1.9 | 66.3 | 72.9 | 65 | 67.6 |
| BC-3 GFP EBV cl-6 | 9.3 | 8.2 | 8.0 | 6.2 | 5.1 | 9.2 | 66.0 | 67.3 | 5.0 | 60.9 |
| BC-3 GFP EBV cl-10 | 7.1 | 9.0 | 6.4 | 14.2 | 5.1 | 11.6 | 63.3 | 70.0 | 8.6 | 66.4 |
| CRO-AP/6 | 14.2 | 11.5 | 1.0 | 80.0 | 1.6 | 7.3 | 66.9 | 82.4 | 78.3 | 81.5 |
| CRO-AP/6 GFPEBV cl-1 | 11.3 | 14.9 | 11.1 | 25.3 | 19.0 | 11.1 | 69.7 | 71.7 | 12.3 | 78.3 |
| CRO-AP/6 GFPEBV cl-2 | 25.5 | 27.8 | 5.1 | 12.2 | 4.4 | 14.9 | 78.6 | 77.7 | 7.9 | 85.0 |
| CRO-AP/3 | 4.7 | 12.8 | 11 | 59.11 | 5 | 10.6 | 11.9 | 19.3 | 60 | 71.6 |
| CRO-AP/3 GFPEBV cl-1 | 4.9 | 9.2 | 6.5 | 12.8 | 4 | 5.3 | 4.3 | 5 | 11.2 | 17.9 |
| CRO-AP/3 GFPEBV cl-2 | 7 | 4.7 | 6.1 | 13.2 | 4.7 | 1 | 4.2 | 2.4 | 10.3 | 22 |
Reactivity with different monoclonal antibodies was measured by indirect immunofluorescence. One representative experiment of 3. Figures indicate percent of positive cells. Figures in bold show major changes.